| Nephrotic Syndrome
Rayos vs Flexbumin 25%
Side-by-side clinical, coverage, and cost comparison for nephrotic syndrome.Deep comparison between: Rayos vs Flexbumin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFlexbumin has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Flexbumin but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Flexbumin
At A Glance
Oral
Daily
Corticosteroid
IV infusion
Human albumin / plasma volume expander
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Hypoalbuminemia
- Respiratory Distress Syndrome, Adult
- Nephrotic Syndrome
- Erythroblastosis, Fetal
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Hypovolemic Shock Infants and young children: 2.5 to 5 mL per kg body weight IV; older children and adults: initial dose 100 to 200 mL IV, repeated after 15 to 30 minutes if response is inadequate. Do not exceed 1 mL/min in patients with normal blood volume.
Hypoalbuminemia Calculate body albumin compartment to be 80 to 100 mL per kg body weight; do not exceed a daily dose of 2 g of albumin per kg of body weight, administered IV.
Burns Dose determined by patient's condition and response to treatment after the first 24 hours, administered IV.
Erythroblastosis, Fetal 1 g per kilogram body weight IV prior to or during exchange transfusion.
Contraindications
- Known hypersensitivity to prednisone or any excipient
- History of hypersensitivity reaction to albumin preparations or to any excipient (N-acetyltryptophan and sodium caprylate)
- Severe anemia or cardiac failure with normal or increased intravascular volume
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Serious Hypersensitivity reaction, anaphylactic reaction, pulmonary edema
Postmarketing Anaphylactic shock, anaphylactic reaction, hypersensitivity/allergic reactions, headache, dysgeusia, myocardial infarction, atrial fibrillation, tachycardia, hypotension, flushing, pulmonary edema, dyspnea, vomiting, nausea, urticaria, rash, pruritus, pyrexia, chills
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Human albumin accounts for 70 to 80% of the colloid osmotic pressure of normal plasma and serves as a transport protein; administered as a 25% IV solution, it draws approximately 3.5 times its volume of additional fluid into the circulation within 15 minutes, expanding blood volume.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Flexbumin
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Flexbumin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Flexbumin
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
No savings programs available for Flexbumin.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FlexbuminView full Flexbumin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.